Translate Bio Names Daniella Beckman to Board of Directors
Biotechnology company Translate Bio today announced the appointment of Daniella Beckman to its board of directors.
Beckman currently provides consulting and interim chief financial officer services for early-stage biotechnology companies, among them Tango Therapeutics and Neon Therapeutics. She worked as chief financial officer of Idenix Pharmaceuticals until it was acquired by Merck in 2014. Prior to that role, Beckman served as Idenix’s corporate controller. Earlier in her career, she held various finance positions at Coley Pharmaceuticals, Biogen Idec and PricewaterhouseCoopers. Beckman earned a B.A. in business administration and accounting from Boston University.
“Daniella joins our board of directors at an exciting time for Translate Bio,” said Ronald Renaud, Translate Bio’s CEO. “Her financial and operational expertise will be vital as we continue to build the company and bring our first product candidate into the clinic for the treatment of cystic fibrosis in early 2018.”